

cyclopharm

Nuclear Medicine



21 May 2008

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclomedica
molecularimaging
technegas

Cyclopharm Limited
ABN 74 116 931 250
Suite 630 Level 6
1 Queens Road
Melbourne Victoria 3004
Australia
T 61 3 9867 2811
F 61 3 9820 5957
www.cyclopharm.com

Cyclopharm receives regulatory approval in Brazil and records its first sales in Mexico

Cyclopharm Limited (ASX: CYC) is delighted to announce it has received regulatory approval for the sale of Technegas products in Brazil. This is a significant achievement for our company and coincides with our first sales of Technegas products in Mexico.

Brazil represents that largest market for nuclear medicine in Latin America and our approval is the result of several years of work. There are approximately 350 nuclear medical centres in Brazil, which also enjoys the highest medical rebate for lung scanning in Latin America.

We are very pleased with this result and expect both Brazil and Mexico to make significant contributions towards the growth of Technegas in Latin America in future years.

John Sharman
Managing Director

Contact details:

Mr John Sharman
Managing Director
Cyclopharm Limited
T +61 3 9867 2811

Mr William Richardson
Company Secretary
Cyclopharm Limited
T +61 3 9867 2811